Europe Preclinical Imaging Market (2024-2029)
The Europe Preclinical Imaging Market was valued at $1257.5 Million in 2024 and projected to reach to $1570.6 Million by 2029, representing a compound annual growth rate of 4.5%. Europe's preclinical imaging market is positioned for moderate but consistent growth through 2029, supported by continued investment in pharmaceutical R&D and the region's commitment to advanced research methodologies.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Europe Preclinical Imaging Market Trends and Insights
- Europe maintains a significant share of the global preclinical imaging landscape, driven by robust pharmaceutical research infrastructure, advanced academic institutions, and stringent regulatory frameworks that mandate comprehensive preclinical testing.
- The region's investment in drug discovery and development continues to fuel demand for sophisticated imaging technologies across Europe. Throughout the forecast period from 2024 to 2029, Europe is expected to experience steady growth in preclinical imaging adoption, supported by increasing R&D spending and the expansion of contract research organizations (CROs) across the continent.
- Europe's commitment to precision medicine and translational research further accelerates the uptake of advanced imaging modalities.
- The market growth in Europe reflects both technological innovation and the region's emphasis on reducing animal testing through improved imaging capabilities, positioning Europe as a key driver of preclinical imaging advancement globally..
Key Market Statistics
- CAGR (2024-2029) 4.5% CAGR
- Market Size, 2024 ~USD 1257.5 Million
- Forecast, 2029 ~USD 1570.6 Million
- Geography Europe
Europe Preclinical Imaging Market Overview
Market Valuation & Growth :
Europe's preclinical imaging market reached $1,257.5 million in 2024 and is forecast to expand to $1,570.6 million by 2029, representing a steady 4.5% CAGR, slightly below the global average of 5%.
Regulatory & Infrastructure Strength :
Europe benefits from stringent regulatory frameworks and world-class pharmaceutical research infrastructure, with advanced academic institutions driving innovation in preclinical imaging technologies and methodologies.
Regional Market Leadership :
Germany, France, and the UK lead Europe's preclinical imaging adoption, collectively representing significant market share due to their robust biotech sectors and investment in research and development.
Competitive Landscape :
Europe maintains a substantial portion of the global preclinical imaging market, competing with North America and Asia-Pacific through established research networks and regulatory compliance expertise.
Europe Preclinical Imaging Market Dynamics
- The market benefits from stringent regulatory requirements that mandate comprehensive preclinical testing, driving demand for sophisticated imaging solutions across academic and commercial laboratories. Key growth drivers include increasing adoption of multimodal imaging systems, expansion of contract research organizations (CROs), and rising collaboration between European institutions and global pharmaceutical companies.
- However, growth remains tempered compared to global rates due to market maturity and budget constraints in some regions.
- Strategic partnerships and technological innovation will be critical for sustained expansion..
Market Ecosystem
Related Ecosystem
Diagnostic Imaging
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT)
- CT Scanners
- Nuclear Imaging
- Positron Emission Tomography
- Siemens healthineers
- PHILIPS HEALTHCARE
- CANON INC.
- FUJIFILM Holdings Corporation
- UNITED IMAGING HEALTHCARE CO., LTD.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- CONMED Corporation
Key Takeaways
- Europe's preclinical imaging market is valued at $1,257.5 million in 2024 and will reach $1,570.6 million by 2029, representing a 4.5% CAGR.
- Europe's stringent regulatory environment and advanced research infrastructure drive consistent demand for preclinical imaging technologies.
- The region's focus on precision medicine and translational research accelerates adoption of innovative imaging modalities across Europe.
- Europe's emphasis on reducing animal testing through improved imaging capabilities positions the region as a leader in ethical research practices.
Preclinical Imaging Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | NUCLEAR IMAGING SYSTEMS (Type) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 5% from 2024 to 2029 |
| Largest Segment | PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES (End User) |
| Market Size Base Year (Billions) | ~USD 4 (2024) |
| Revenue Forecast (Billions) | ~USD 5.1 (2029) |
| Segments Covered | Product, Type, Application, End User |
Europe Preclinical Imaging Market Report Segmentation
4 segment dimensions are covered across the global market.
By Product
- Imaging Systems
- Reagents
- Software
By Type
- Barium-Based Contrast Agents
- Bioluminescence Imaging Systems
- Fluorescence Imaging Systems
- Gadolinium-Based Contrast Agents
- Gallium-67-Based Spect Probes
- Gastrografin-Based Contrast Agents
- Gold Nanoparticles
- Iodine-131-Based Spect Probes
- Iodine-Based Contrast Agents
- Iron-Based Contrast Agents
- Magnetic Particle Imaging Systems
- Manganese-Based Contrast Agents
- Micro-Ct Systems
- Micro-Mri Systems
- Micro-Ultrasound Systems
- Nuclear Imaging Systems
- Optical Imaging Systems
- Other Optical Imaging Systems
- Other Spect Probes
- Photoacoustic Imaging Systems
- Technetium-99M-Based Spect Probes
- Thallium-201-Based Spect Probes
By Application
- Cardiology
- Immunology & Inflammation
- Infectious Diseases
- Neurology
- Oncology
- Other Applications
By End User
- Academic & Research Centers
- Imaging Centers
- Other End Users
- Pharmaceutical & Biotechnology Companies
EUROPE: PRECLINICAL IMAGING MARKET, BY END USER, 2023–2029
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH CENTERS | 192.4 | 201.7 | 211.3 | 221.4 | 232 | 243 | 254.6 | 4.8 |
| IMAGING CENTERS | 108.3 | 113.9 | 119.8 | 126 | 132.5 | 139.3 | 146.5 | 5.2 |
| OTHER END USERS | 48.1 | 49.7 | 51.4 | 53.2 | 55 | 56.8 | 58.7 | 3.4 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 854 | 892.3 | 932.3 | 974 | 1017.6 | 1063.2 | 1110.7 | 4.5 |
| TOTAL | 1202.8 | 1257.5 | 1314.8 | 1374.6 | 1437 | 1502.4 | 1570.6 | 4.5 |
REST OF EUROPE: PRECLINICAL IMAGING MARKET, BY END USER, 2023–2029
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH CENTERS | 15.7 | 16.3 | 17 | 17.6 | 18.3 | 19.1 | 19.8 | 4 |
| IMAGING CENTERS | 8.8 | 9.2 | 9.6 | 10 | 10.5 | 10.9 | 11.4 | 4.4 |
| OTHER END USERS | 3.9 | 4 | 4.1 | 4.2 | 4.3 | 4.5 | 4.6 | 2.6 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 69.6 | 72.2 | 74.8 | 77.6 | 80.5 | 83.4 | 86.5 | 3.7 |
| TOTAL | 98 | 101.7 | 105.5 | 109.5 | 113.6 | 117.8 | 122.2 | 3.8 |
Target Audience
- Pharmaceutical & Biotech Companies : European and global pharma firms need detailed market intelligence to optimize preclinical imaging investments, streamline R&D operations, and identify regional partnership opportunities.
- Contract Research Organizations (CROs) : CROs operating in Europe require market data to assess demand for preclinical imaging services, benchmark service offerings, and plan capacity expansion across key European markets.
- Medical Device & Imaging Equipment Manufacturers : Imaging technology providers need regional market insights to tailor product development, pricing strategies, and go-to-market approaches for European research institutions and commercial labs.
- Academic & Research Institutions : European universities and research centers use market data to justify funding requests, benchmark facility capabilities, and identify collaboration opportunities with industry partners.
- Investment & Venture Capital Firms : Investors targeting the European preclinical imaging sector require comprehensive market analysis to evaluate portfolio opportunities, assess growth potential, and make informed funding decisions.
Key Companies in the Europe Preclinical Imaging Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| PATHEON INC | Netherlands | Private Company | Optical Imaging (Bioluminescance),PET,SPECT, |
| ANALOGIC CORPORATION | United States | Private Company | MRI,PET,SPECT, |
| XILINX, INC. | United States | Private Company | Optical Imaging (Bioluminescance),PET,SPECT, |
| GUERBET GROUP | France | InvalidIdentifier | PET,SPECT,MRI, |
| BRUKER CORPORATION | United States | Public Company | MRI,PET,SPECT, |
| REVVITY, INC. | United States | Public Company | Optical Imaging (Bioluminescance),PET,SPECT, |
| OPTISCAN IMAGING LTD. | Australia | Public Company | Optical Imaging (Bioluminescance),PET,SPECT, |
PATHEON INC
Patheon Inc. is a Netherlands-based private company with 9,100 employees operating in the pharmaceutical and life sciences sector.
ANALOGIC CORPORATION
Analogic Corporation is a United States-based private company founded in 1967 with 1,510 employees, specializing in medical and aerospace technology solutions.
XILINX, INC.
Xilinx, Inc. is a United States-based private company founded in 1984 with 4,890 employees, operating in the semiconductor and programmable logic industry.
GUERBET GROUP
Guerbet Group is a France-based company in the medical imaging and pharmaceutical sector.
BRUKER CORPORATION
Bruker Corporation is a United States-based public company founded in 1960 with 11,085 employees, providing scientific instruments and analytical solutions.
REVVITY, INC.
Revvity, Inc. is a United States-based public company founded in 1937 with 11,000 employees, operating in the life sciences and diagnostics industry.
OPTISCAN IMAGING LTD.
Optiscan Imaging Ltd. is an Australia-based public company founded in 1994 with 9 employees, specializing in optical imaging technology.
Countries within Europe - compare and drill down
| Country | 2025 size (native) |
|---|---|
| Germany | USD 42.2 Million |
| UK | USD 33.1 Million |
| France | USD 33.6 Million |
| Italy | USD 14.2 Million |
| Spain | USD 13 Million |
Country market size visualization
Reasons to Buy this Report
- Regional Market Sizing & Forecasts : Obtain precise market valuations for Europe's preclinical imaging sector with country-level breakdowns for Germany, UK, France, Italy, and Spain, enabling targeted investment and expansion strategies.
- Regulatory & Compliance Insights : Understand Europe's stringent regulatory landscape and how it shapes preclinical imaging adoption, helping stakeholders navigate compliance requirements and market entry strategies.
- Competitive Positioning Analysis : Benchmark your organization against regional competitors and identify market gaps, growth opportunities, and emerging trends specific to the European preclinical imaging ecosystem.
- Investment & Partnership Opportunities : Identify high-growth markets within Europe and key institutional players driving preclinical imaging adoption, facilitating strategic partnerships and capital allocation decisions.
- Technology & Innovation Trends : Stay informed on emerging preclinical imaging technologies and methodologies gaining traction in European research institutions and pharmaceutical companies through 2029.
Frequently asked questions
What is the current size of Europe's preclinical imaging market?
Europe's preclinical imaging market was valued at $1,257.5 million in 2024 and is expected to grow to $1,570.6 million by 2029.
What is the projected growth rate for preclinical imaging in Europe?
Europe's preclinical imaging market is projected to grow at a compound annual growth rate (CAGR) of 4.5% from 2024 to 2029.
What factors drive preclinical imaging demand in Europe?
Europe's demand for preclinical imaging is driven by robust pharmaceutical R&D infrastructure, stringent regulatory requirements, advanced academic institutions, and a commitment to precision medicine and ethical research practices.
How does Europe's preclinical imaging market compare to global trends?
Europe's 4.5% CAGR is slightly lower than the global 5% CAGR, reflecting the region's mature market status while maintaining strong absolute market value and innovation leadership.
Which imaging technologies are most prevalent in Europe's preclinical market?
Europe's preclinical imaging market encompasses MRI, CT, PET, ultrasound, and optical imaging technologies, with adoption driven by research applications in drug discovery and development.
RESEARCH METHODOLOGY
This market research study utilized extensive secondary sources, directories, and databases to identify and collect information relevant to this technical, market-oriented, and financial analysis of the preclinical imaging market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to gather and verify critical qualitative and quantitative information, as well as to assess market prospects. The size of the preclinical imaging market was estimated through various secondary research approaches and triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was employed to identify and collect information relevant to the comprehensive, technical, market-oriented, and commercial study of the preclinical imaging market. It was also used to obtain important information about key players, market classification, and segmentation according to industry trends, as well as key developments related to market and technology perspectives, down to the most detailed level. A database of the key industry leaders was also prepared using secondary research.
Primary Research
Extensive primary research was conducted after acquiring a basic understanding of the global preclinical imaging market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (hospital personnel, department heads, hospital directors, corporate personnel) and supply side (such as C-level and D-level executives, technology experts, software developers, marketing and sales managers, among others) across five major regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
Breakdown of Primary Interviews
Note: Tiers are defined based on the total revenues of companies. As of 2024, Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the global preclinical imaging market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- Key players in the global preclinical imaging market were identified through secondary research, and their global market shares were determined through primary and secondary research.
- The research methodology included the study of the annual and quarterly financial reports and regulatory filings, data books of major market players, and interviews with industry experts for detailed market insights.
- All percentage shares, splits, and breakdowns for the global preclinical imaging market were determined by using secondary sources and verified through primary sources.
- All key macroindicators affecting the revenue growth of market segments and subsegments have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get validated and verified quantitative and qualitative data.
- The gathered market data was consolidated and added with detailed inputs and analysis and presented in this report.
Global Preclinical Imaging Market: Bottom-up and Top-down Approach
Data Triangulation
After arriving at the overall market size, from the market size estimation process explained above, the preclinical imaging market was split into segments and subsegments. To complete the overall market engineering process and to arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the preclinical imaging market.
Market Definition
Preclinical imaging involves the application of molecular imaging for the assessment of anatomical, physiological, and functional parameters in live animal models during preclinical studies. Preclinical imaging systems and reagents are utilized to visualize living animals in order to assess the safety and efficacy of novel drug procedures or other medical treatments for human applications. During preclinical studies, a variety of different imaging modalities are utilized, such as optical imaging systems, nuclear imaging systems (micro-PET and micro-SPECT), micro-MRI, micro-ultrasound systems, and micro-CT imaging systems.
Stakeholders
- Preclinical Imaging Instrument Manufacturers, Suppliers, and Imaging Software Providers
- Pharmaceutical and Biotechnology Companies
- Preclinical Imaging Reagent Manufacturers and Suppliers
- Contract Research Organizations (CROs)
- Research and Development (R&D) Companies
- Government Research Laboratories
- Independent Research Laboratories
- Government and Independent Regulatory Authorities
- Medical Research Laboratories
- Academic Medical Institutes and Universities
- Market Research and Consulting Service Providers
Report Objectives
- To define, describe, and forecast the preclinical imaging market by product type, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
-
To analyze the opportunities in the market for stakeholders and provide details of
the competitive landscape for preclinical imaging market leaders - To profile the key players in the market and comprehensively analyze their market shares and core competencies
-
To forecast the size of the market segments with respect to five main regions:
North America, the Asia Pacific, Europe, Latin America, and the Middle East & Africa - To track and analyze competitive developments, such as partnerships, acquisitions, product launches & approvals, and expansions
- To benchmark players within the preclinical imaging market using the Competitive Evaluation Matrix, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offering
Get the Full Preclinical Imaging Market Report
Full forecast, segment splits, and company analysis for all Preclinical Imaging Market.
- US Preclinical Imaging Market
- Canada Preclinical Imaging Market
- Germany Preclinical Imaging Market
- UK Preclinical Imaging Market
- France Preclinical Imaging Market
- Italy Preclinical Imaging Market
- Spain Preclinical Imaging Market
- Japan Preclinical Imaging Market
- China Preclinical Imaging Market
- India Preclinical Imaging Market
- Brazil Preclinical Imaging Market
- Mexico Preclinical Imaging Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
